NMRA 266
Alternative Names: NMRA-266Latest Information Update: 19 Apr 2024
At a glance
- Originator Vanderbilt University
- Developer Neumora Therapeutics; Vanderbilt University
- Class Antipsychotics; Behavioural disorder therapies; Small molecules
- Mechanism of Action Muscarinic M4 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Schizophrenia
- Preclinical Psychiatric disorders
Most Recent Events
- 15 Apr 2024 US FDA places clinical hold on phase-I trial of NMRA 266 for Schizophrenia (In volunteers) in USA
- 27 Nov 2023 Neumora Therapeutics has patent protection for NMRA 266 from Vanderbilt University, including composition of matter patent extending to 2042
- 27 Nov 2023 Phase-I clinical trials in Schizophrenia (In volunteers) in USA (PO)